MA41778A - Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine - Google Patents
Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaineInfo
- Publication number
- MA41778A MA41778A MA041778A MA41778A MA41778A MA 41778 A MA41778 A MA 41778A MA 041778 A MA041778 A MA 041778A MA 41778 A MA41778 A MA 41778A MA 41778 A MA41778 A MA 41778A
- Authority
- MA
- Morocco
- Prior art keywords
- benzimidazole derivatives
- bromodomain inhibitors
- compounds
- formula
- salts
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Epidemiology (AREA)
Abstract
Composés de formule (i) et leurs sels: dans lesquels r1, r2, r3, r4 sont définis ici. Les composés de formule (i) et leurs sels inhibent la liaison de la famille bet des protéines de bromodomaïne à, par exemple, des résidus de lysine acétylés et peuvent donc être utilisés en thérapie, par exemple dans le traitement de maladies auto-immunes et inflammatoires, comme la polyarthrite rhumatoïde; et les cancers.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1504689.9A GB201504689D0 (en) | 2015-03-19 | 2015-03-19 | Chemical compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
MA41778A true MA41778A (fr) | 2018-01-24 |
Family
ID=53052091
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA046981A MA46981A (fr) | 2015-03-19 | 2016-03-17 | Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine |
MA041778A MA41778A (fr) | 2015-03-19 | 2016-03-17 | Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA046981A MA46981A (fr) | 2015-03-19 | 2016-03-17 | Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine |
Country Status (35)
Country | Link |
---|---|
US (2) | US10442786B2 (fr) |
EP (2) | EP3549939A1 (fr) |
JP (1) | JP6419990B2 (fr) |
KR (1) | KR102072850B1 (fr) |
CN (1) | CN107635989B (fr) |
AR (1) | AR103934A1 (fr) |
AU (1) | AU2016232217B2 (fr) |
BR (1) | BR112017019779B1 (fr) |
CA (1) | CA2979504C (fr) |
CL (1) | CL2017002332A1 (fr) |
CO (1) | CO2017009992A2 (fr) |
CR (1) | CR20170430A (fr) |
CY (1) | CY1121855T1 (fr) |
DK (1) | DK3271349T3 (fr) |
DO (1) | DOP2017000213A (fr) |
EA (1) | EA033594B1 (fr) |
ES (1) | ES2735417T3 (fr) |
GB (1) | GB201504689D0 (fr) |
HR (1) | HRP20191186T1 (fr) |
HU (1) | HUE044414T2 (fr) |
IL (1) | IL254318B (fr) |
LT (1) | LT3271349T (fr) |
MA (2) | MA46981A (fr) |
ME (1) | ME03485B (fr) |
MX (1) | MX2017012023A (fr) |
PE (1) | PE20180032A1 (fr) |
PH (1) | PH12017501620A1 (fr) |
PL (1) | PL3271349T3 (fr) |
PT (1) | PT3271349T (fr) |
RS (1) | RS59056B1 (fr) |
SG (1) | SG11201707356QA (fr) |
SI (1) | SI3271349T1 (fr) |
TW (1) | TW201706257A (fr) |
UY (1) | UY36589A (fr) |
WO (1) | WO2016146738A1 (fr) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201504689D0 (en) * | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
CN108290856A (zh) | 2015-08-11 | 2018-07-17 | 尼奥迈德研究所 | 芳基-取代的二氢喹诺酮、它们的制备和它们作为药物的用途 |
US10836742B2 (en) | 2015-08-11 | 2020-11-17 | Neomed Institute | N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals |
CA2994478C (fr) | 2015-08-12 | 2023-10-03 | Neomed Institute | Benzimidazoles substitues, preparation et utilisation de ceux-ci en tant qu'agents pharmaceutiques |
WO2017066876A1 (fr) | 2015-10-21 | 2017-04-27 | Neomed Institute | Imidazopyridines substituées, leur préparation et leur utilisation comme médicaments |
WO2017127930A1 (fr) | 2016-01-28 | 2017-08-03 | Neomed Institute | [1,2,4]triazolo[4,3-a]pyridines substituées, leur préparation et leur utilisation comme médicaments |
GB201614939D0 (en) * | 2016-09-02 | 2016-10-19 | Glaxosmithkline Ip Dev Ltd | Crystalline hydrate |
GB201614940D0 (en) * | 2016-09-02 | 2016-10-19 | Glaxosmithkline Intellectual Property (No 2) Ltd | Chemical compounds |
GB201614934D0 (en) * | 2016-09-02 | 2016-10-19 | Glaxosmithkline Intellectual Property (No 2) Ltd | Chemical compounds |
TWI788343B (zh) * | 2017-04-18 | 2023-01-01 | 美商塞爾基因定量細胞研究公司 | 治療用化合物 |
CN109280046B (zh) * | 2017-07-21 | 2021-02-02 | 浙江海正药业股份有限公司 | 苯并咪唑类衍生物及其制备方法及其在医药上的用途 |
EP3750885A4 (fr) * | 2018-02-06 | 2021-10-27 | Shanghai Haihe Pharmaceutical Co., Ltd. | Composé présentant une activité inhibitrice de bet, son procédé de préparation et son utilisation |
CN109369432B (zh) * | 2018-11-02 | 2021-06-25 | 永农生物科学有限公司 | (s)-4-氯-2-氨基丁酸酯的制备方法 |
JP2022053557A (ja) * | 2019-02-08 | 2022-04-06 | マルホ株式会社 | ピリドン誘導体 |
CN113874017A (zh) * | 2019-03-15 | 2021-12-31 | 福马治疗股份有限公司 | 抑制环amp-应答元件结合蛋白(creb) |
US20220259200A1 (en) * | 2019-04-24 | 2022-08-18 | Convergene, Llc | Small molecule bromodomain inhibitors and uses therof |
US20220227709A1 (en) * | 2019-04-29 | 2022-07-21 | The Board Of Regents Of The University Of Texas System | Compositions and methods for treating schistosoma infections |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
GB0201677D0 (en) | 2002-01-25 | 2002-03-13 | Glaxo Group Ltd | Medicament dispenser |
GB0515584D0 (en) | 2005-07-28 | 2005-09-07 | Glaxo Group Ltd | Medicament dispenser |
AR058289A1 (es) | 2005-12-12 | 2008-01-30 | Glaxo Group Ltd | Colector para ser usado en dispensador de medicamento |
PT2007752E (pt) | 2006-03-31 | 2010-10-18 | Janssen Pharmaceutica Nv | Benzoimidazol-2-il pirimidinas e pirazinas como moduladores do receptor de histamina h4 |
JP2013508461A (ja) * | 2009-10-27 | 2013-03-07 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー | 脂肪酸シンターゼ阻害剤としてのベンズイミダゾール |
GB0919434D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
WO2012047538A1 (fr) | 2010-10-06 | 2012-04-12 | Glaxosmithkline Llc | Dérivés de benzimidazole utilisés comme inhibiteurs de pi3 kinase |
GB201114103D0 (en) * | 2011-08-17 | 2011-09-28 | Glaxosmithkline Llc | Novel compounds |
WO2013097052A1 (fr) * | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Inhibiteurs de bromodomaine |
MX2015007921A (es) * | 2012-12-21 | 2016-03-03 | Zenith Epigenetics Corp | Compuestos heterociclicos novedosos como inhibidores de bromodominio. |
MX2015012456A (es) | 2013-03-15 | 2016-02-03 | Plexxikon Inc | Compuestos heterociclicos y usos de los mismos. |
TWI530499B (zh) | 2013-03-28 | 2016-04-21 | 吉李德科學股份有限公司 | 作為溴結構域(bromodomain)抑制劑之苯並咪唑酮衍生物類 |
TWI527811B (zh) | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
WO2015004534A2 (fr) * | 2013-06-21 | 2015-01-15 | Zenith Epigenetics Corp. | Nouveaux composés hétérocycliques utilisés en tant qu'inhibiteurs de bromodomaine |
US20150051208A1 (en) * | 2013-08-14 | 2015-02-19 | Boehringer Ingelheim International Gmbh | Pyridinones |
US9428515B2 (en) * | 2014-05-09 | 2016-08-30 | Boehringer Ingelheim International Gmbh | Benzimidazole derivatives |
GB201504689D0 (en) * | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Chemical compounds |
GB201504694D0 (en) * | 2015-03-19 | 2015-05-06 | Glaxosmithkline Ip Dev Ltd | Covalent conjugates |
GB201614939D0 (en) * | 2016-09-02 | 2016-10-19 | Glaxosmithkline Ip Dev Ltd | Crystalline hydrate |
-
2015
- 2015-03-19 GB GBGB1504689.9A patent/GB201504689D0/en not_active Ceased
-
2016
- 2016-03-15 AR ARP160100683A patent/AR103934A1/es unknown
- 2016-03-17 SI SI201630321T patent/SI3271349T1/sl unknown
- 2016-03-17 EA EA201791973A patent/EA033594B1/ru not_active IP Right Cessation
- 2016-03-17 PE PE2017001543A patent/PE20180032A1/es unknown
- 2016-03-17 HU HUE16710214 patent/HUE044414T2/hu unknown
- 2016-03-17 MA MA046981A patent/MA46981A/fr unknown
- 2016-03-17 SG SG11201707356QA patent/SG11201707356QA/en unknown
- 2016-03-17 UY UY0001036589A patent/UY36589A/es not_active Application Discontinuation
- 2016-03-17 MA MA041778A patent/MA41778A/fr unknown
- 2016-03-17 TW TW105108340A patent/TW201706257A/zh unknown
- 2016-03-17 WO PCT/EP2016/055792 patent/WO2016146738A1/fr active Application Filing
- 2016-03-17 JP JP2017548404A patent/JP6419990B2/ja active Active
- 2016-03-17 CN CN201680027314.8A patent/CN107635989B/zh active Active
- 2016-03-17 ME MEP-2019-171A patent/ME03485B/fr unknown
- 2016-03-17 RS RS20190986A patent/RS59056B1/sr unknown
- 2016-03-17 PT PT16710214T patent/PT3271349T/pt unknown
- 2016-03-17 PL PL16710214T patent/PL3271349T3/pl unknown
- 2016-03-17 US US15/559,556 patent/US10442786B2/en active Active
- 2016-03-17 CR CR20170430A patent/CR20170430A/es unknown
- 2016-03-17 DK DK16710214.4T patent/DK3271349T3/da active
- 2016-03-17 MX MX2017012023A patent/MX2017012023A/es unknown
- 2016-03-17 EP EP19174047.1A patent/EP3549939A1/fr not_active Withdrawn
- 2016-03-17 AU AU2016232217A patent/AU2016232217B2/en not_active Ceased
- 2016-03-17 CA CA2979504A patent/CA2979504C/fr active Active
- 2016-03-17 KR KR1020177030073A patent/KR102072850B1/ko active IP Right Grant
- 2016-03-17 ES ES16710214T patent/ES2735417T3/es active Active
- 2016-03-17 BR BR112017019779-0A patent/BR112017019779B1/pt active IP Right Grant
- 2016-03-17 EP EP16710214.4A patent/EP3271349B1/fr active Active
- 2016-03-17 LT LTEP16710214.4T patent/LT3271349T/lt unknown
-
2017
- 2017-09-04 IL IL254318A patent/IL254318B/en active IP Right Grant
- 2017-09-07 PH PH12017501620A patent/PH12017501620A1/en unknown
- 2017-09-14 CL CL2017002332A patent/CL2017002332A1/es unknown
- 2017-09-19 DO DO2017000213A patent/DOP2017000213A/es unknown
- 2017-09-29 CO CONC2017/0009992A patent/CO2017009992A2/es unknown
-
2019
- 2019-07-01 HR HRP20191186TT patent/HRP20191186T1/hr unknown
- 2019-07-26 CY CY20191100796T patent/CY1121855T1/el unknown
- 2019-08-22 US US16/547,909 patent/US11053212B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA41778A (fr) | Dérivés de benzimidazole en tant qu'inhibiteurs de bromodomaine | |
MA52486B1 (fr) | Pyridazinones utilisés en tant qu'inhibiteurs de parp7 | |
EA202092896A1 (ru) | Гетероциклические и гетероарильные соединения для лечения болезни гентингтона | |
MA40111A1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
EA202092899A1 (ru) | Гетероарильные соединения для лечения болезни гентингтона | |
EA202091508A1 (ru) | 6-азаиндольные соединения | |
EA201891203A1 (ru) | Гетероциклические соединения в качестве иммуномодуляторов | |
EA201792047A1 (ru) | Новые соединения | |
MA43169B1 (fr) | Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma | |
MA39783B1 (fr) | Dérivés de quinoxaline utiles en tant que modulateurs de la fgfr kinase | |
EA201890338A1 (ru) | Оксадиазольные производные, пригодные в качестве ингибиторов hdac | |
EA201792229A1 (ru) | Ингибиторы бромодомена | |
MA44674B1 (fr) | Inhibiteurs de bromodomaine | |
EA201691151A1 (ru) | Соединения для лечения пациентов с ros1-мутантными раковыми клетками | |
CY1120846T1 (el) | 2-αμινο-6-(διφθορομεθυλ)-5,5-διφθορο-6-φαινυλ-3,4,5,6-τετραϋδροπυριδινες ως αναστολεις bace1 | |
MA41238A (fr) | Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit | |
EA201990410A1 (ru) | Производные имидазола и их применение в лечении аутоиммунных или воспалительных заболеваний или раковых заболеваний | |
EA201991387A1 (ru) | ТРИЦИКЛИЧЕСКИЕ ЕНОНЫ - ПРОИЗВОДНЫЕ ПИРИМИДИНА ДЛЯ ИНГИБИРОВАНИЯ ROR-γ И ДРУГИХ ПРИМЕНЕНИЙ | |
MA39170A1 (fr) | Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer | |
EA202090414A1 (ru) | Соединения и их применение | |
EA202191478A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
EA202190588A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
EA202191477A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
EA202092446A1 (ru) | ТИАЗОЛ- ИЛИ ТИАДИАЗОЛЗАМЕЩЕННЫЕ АРИЛЬНЫЕ И ГЕТЕРОАРИЛЬНЫЕ ПРОИЗВОДНЫЕ КАК ИНГИБИТОРЫ Vps34 | |
EA202190452A1 (ru) | Ингибиторы cdk8/19 |